Trial Profile
A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs H 1PV (Primary) ; H 1PV (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Acronyms ParvOryx02
- Sponsors Oryx GmbH & Co
- 23 Aug 2021 Results published in the Clinical Cancer Research
- 30 Oct 2019 According to an Oryx GmbH & Co media release, final results from this trial were presented at the International Oncolytic Virus Conference at the Mayo Clinic Center in Rochester (October 9-12, 2019).
- 30 Oct 2019 According to an Oryx GmbH & Co media release, Preliminary data from this trial were presented at the Oncolytic Virus Immunotherapy Summit in London (March 20-21, 2019).